Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sinovac Biotech Ltd (SVA)

Sinovac Biotech Ltd (SVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 368,919
  • Shares Outstanding, K 57,019
  • Annual Sales, $ 1,493 M
  • Annual Income, $ 113,870 K
  • 60-Month Beta 0.35
  • Price/Sales 1.83
  • Price/Cash Flow 0.00
  • Price/Book N/A
Trade SVA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 05/06/24
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.25 +3.52%
on 02/22/19
6.69 -3.29%
on 02/12/19
-0.03 (-0.46%)
since 01/22/19
3-Month
5.73 +12.91%
on 12/21/18
7.50 -13.73%
on 12/03/18
-0.73 (-10.14%)
since 11/21/18
52-Week
5.73 +12.91%
on 12/21/18
8.75 -26.06%
on 03/22/18
-1.65 (-20.32%)
since 02/22/18

Most Recent Stories

More News
SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2022 annual report on Form 20-F with the U.S. Securities...

SVA.TO : 0.4750 (+1.06%)
SVA : 6.47 (-0.31%)
Sinovac Amends Shareholder Rights Plan

Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder...

SVA.TO : 0.4750 (+1.06%)
SVA : 6.47 (-0.31%)
SINOVAC Reports Unaudited First Half of 2022 Financial Results

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended...

SVA.TO : 0.4750 (+1.06%)
SVA : 6.47 (-0.31%)
SINOVAC Varicella Vaccine Prequalified by WHO

Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that it received prequalification from the World Health...

SVA.TO : 0.4750 (+1.06%)
SVA : 6.47 (-0.31%)
SINOVAC to Showcase Products at CPHI Frankfurt

Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of...

SVA.TO : 0.4750 (+1.06%)
SVA : 6.47 (-0.31%)
SINOVAC DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sinovac Biotech Ltd. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Sinovac Biotech Ltd. (“Sinovac” or the “Company”)...

SVA.TO : 0.4750 (+1.06%)
SVA : 6.47 (-0.31%)
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Sinovac Biotech Ltd. (SVA) Investors of Class Action Deadline Against 1Globe Capital LLC and to Actively Participate

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against 1Globe Capital LLC (“1Globe”) and certain of its officers, on behalf of...

SVA.TO : 0.4750 (+1.06%)
SVA : 6.47 (-0.31%)
SVA FINAL DEADLINE MONDAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Sinovac Biotech Ltd. Investors to Secure Counsel Before Important October 17 Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers - SVA

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds sellers of the stock of Sinovac Biotech Ltd. (NASDAQ: SVA) between April 11,...

SVA.TO : 0.4750 (+1.06%)
SVA : 6.47 (-0.31%)
SVA FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sinovac Biotech Ltd. Investors to Secure Counsel Before Important October 17 Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers – SVA

WHY: Rosen Law Firm, a global investor rights law firm, reminds sellers of the stock of Sinovac Biotech Ltd. (NASDAQ: SVA) between April 11, 2016 and February 22, 2019, both dates inclusive (the “Class...

SVA.TO : 0.4750 (+1.06%)
SVA : 6.47 (-0.31%)
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Sinovac Biotech Ltd. Investors With Losses to Secure Counsel Before Important October 17 Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers - SVA

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds sellers of the stock of Sinovac Biotech Ltd. (NASDAQ: SVA) between April 11,...

SVA.TO : 0.4750 (+1.06%)
SVA : 6.47 (-0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sonovac Biotech Ltd. specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as hepatitis A and hepatitis B, influenza, `SARS`, and avian flu. Sinovac is one of the leading emerging biotechnology companies in China.

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 6.76
1st Resistance Point 6.62
Last Price 6.47
1st Support Level 6.29
2nd Support Level 6.10
3rd Support Level N/A

See More

52-Week High 8.75
Fibonacci 61.8% 7.60
Fibonacci 50% 7.24
Fibonacci 38.2% 6.88
Last Price 6.47
52-Week Low 5.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar